On April 16 2013 BioInvent reported that the April 15, 2013 online issue of the highly prestigious cancer research journal Cancer Cell features a data publication demonstrating potent anti-cancer activity of BI-505 in multiple preclinical myeloma tumor models (Press release BioInvent, APR 16, 2013, http://www.bioinvent.com/investors/press-releases/release.aspx?releaseid=763773 [SID:1234500563]). BI-505 is currently in Phase I clinical testing and is furthest ahead among several novel antibody candidates that have emerged from the company’s unique function-first platform "F.I.R.S.T.", which enables combined target and antibody drug discovery.
ICAM-1 is a cell adhesion molecule that has previously been pursued as target for antibody based therapy, but then in chronic inflammatory and autoimmune diseases, based on its well-characterized role in inflammation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!